Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Trodelvy® as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies.
[Gilead Sciences, Inc.]
Sorry, but the selected Zotpress account can't be found.